Next Article in Journal
Evaluation of Four Different Analytical Tools to Determine the Regional Origin of Gastrodia elata and Rehmannia glutinosa on the Basis of Metabolomics Study
Next Article in Special Issue
The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
Previous Article in Journal / Special Issue
MicroRNAs in Cervical Cancer: Evidences for a miRNA Profile Deregulated by HPV and Its Impact on Radio-Resistance
Molecules 2014, 19(5), 6282-6293; doi:10.3390/molecules19056282
Communication

Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis

1,4
,
2
,
3
,
3
,
1
,
1,*  and 3,*
1 Laboratory of Cancer Biology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China 2 Department of Anesthesiology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China 3 Department of Clinical Oncology, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China 4 Department of Clinical Oncology, the Children's Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China
* Authors to whom correspondence should be addressed.
Received: 21 February 2014 / Revised: 8 May 2014 / Accepted: 12 May 2014 / Published: 16 May 2014
(This article belongs to the Special Issue miRNAs as Probes to Monitor Cancer and Neurodegenerative Disorders)
View Full-Text   |   Download PDF [319 KB, uploaded 18 June 2014]   |   Browse Figures

Abstract

The objective of this meta-analysis was to determine the diagnostic accuracy of circulating microRNA-155 (miR-155) for breast cancer (BC). PubMed, Embase, EBSCO (ASP/BSP), Cochrane Library and China National Knowledge Infrastructure (CNKI) were searched up to 30 January 2014 for eligible studies. Quality Assessment of Diagnostic Accuracy Studies (QUADAS) was employed to assess the quality of the included studies. Meta-analysis were performed in Meta-Disc 1.4 and Stata 12.0. Three studies with total 184 BC patients and 75 control individuals were included in this meta-analysis. All of the included studies are of high quality (QUADAS scores 12 or 13). The summary estimates revealed that the pooled sensitivity is 79% (95% confidence interval (CI): 72%–84%) and the specificity is 85% (95% CI: 75%–92%), for the diagnosis of breast cancer. In addition, the area under the summary ROC curve (AUC) is 0.9217. The current evidence suggests that circulating miR-155 has the potential diagnostic value with a high sensitivity and specificity for BC. More prospective studies on the diagnostic value of circulating miR-155 for BC are needed in the future.
Keywords: breast cancer; circulating miRNAs; biomarker; microRNA-155 breast cancer; circulating miRNAs; biomarker; microRNA-155
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplement

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Wang, F.; Hou, J.; Jin, W.; Li, J.; Yue, Y.; Jin, H.; Wang, X. Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis. Molecules 2014, 19, 6282-6293.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert